Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Galectin Therapeutic (GALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 104,224
  • Shares Outstanding, K 34,060
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,440 K
  • 36-Month Beta 2.67
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 30.65

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.96 +56.12%
on 03/29/17
3.68 -16.85%
on 04/10/17
+1.03 (+50.74%)
since 03/28/17
3-Month
0.97 +215.46%
on 02/02/17
3.68 -16.85%
on 04/10/17
+2.07 (+209.09%)
since 01/27/17
52-Week
0.49 +524.49%
on 11/03/16
3.68 -16.85%
on 04/10/17
+1.60 (+109.59%)
since 04/28/16

Most Recent Stories

More News
Can The Uptrend Continue for Galectin Therapeutics (GALT)?

Investors certainly have to be happy with Galectin Therapeutics Inc (GALT) and its short term performance

GALT : 3.06 (-3.77%)
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin diseases, and cancer, today announced that the Company has received...

GALT : 3.06 (-3.77%)
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?

Henry Schein, Inc. (HSIC) is expected to report first-quarter 2017 results on May 2, before the opening bell.

SYRS : 15.19 (-3.74%)
GALT : 3.06 (-3.77%)
HSIC : 173.80 (-0.22%)
HRC : 75.64 (+2.44%)
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?

Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.

SYRS : 15.19 (-3.74%)
GALT : 3.06 (-3.77%)
MYGN : 18.39 (+0.33%)
HRC : 75.64 (+2.44%)
Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store?

Edward Lifesciences Corp. (EW) is scheduled to report first-quarter 2017 earnings results after market close on Apr 25.

SYRS : 15.19 (-3.74%)
EW : 109.67 (unch)
GALT : 3.06 (-3.77%)
HRC : 75.64 (+2.44%)
Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings?

Mead Johnson Nutrition Company (MJN) is expected to report first-quarter 2017 results on Apr 27, before the opening bell.

MJN : 88.72 (-0.03%)
SYRS : 15.19 (-3.74%)
GALT : 3.06 (-3.77%)
HRC : 75.64 (+2.44%)
ResMed (RMD) Q3 Earnings: Disappointment in the Cards?

ResMed Inc. (RMD) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.

SYRS : 15.19 (-3.74%)
GALT : 3.06 (-3.77%)
RMD : 67.99 (-6.67%)
HRC : 75.64 (+2.44%)
IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store?

IDEXX Laboratories, Inc. (IDXX) is slated to report first-quarter 2017 results on Apr 28, before the opening bell.

SYRS : 15.19 (-3.74%)
GALT : 3.06 (-3.77%)
HRC : 75.64 (+2.44%)
IDXX : 167.73 (+3.05%)
Can Illumina (ILMN) Spring a Surprise this Earnings Season?

Illumina Inc. (ILMN), a leading provider of tools and integrated systems for analysis of genetic variation and function, is scheduled to report first-quarter 2017 financial results on Apr 25, after the...

SYRS : 15.19 (-3.74%)
GALT : 3.06 (-3.77%)
ILMN : 184.86 (+0.61%)
HRC : 75.64 (+2.44%)
5 Drug Stocks That Could Be Big Winners this Earnings Season

Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.

QURE : 5.36 (-1.83%)
GALT : 3.06 (-3.77%)
BMRN : 95.84 (-0.44%)
ZSAN : 1.64 (+6.49%)
PFE : 33.92 (+0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Support & Resistance

2nd Resistance Point 3.25
1st Resistance Point 3.16
Last Price 3.06
1st Support Level 3.01
2nd Support Level 2.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.